Vitamin A Status and Risk of Excessive Vitamin A Intake Among Urban Filipino Children (GloVitAS-P)

May 3, 2017 updated by: University of California, Davis

Vitamin A Status and Risk of Excessive Vitamin A Intake Among Urban Filipino Children Exposed to Multiple Vitamin A Intervention Programs

The goal of this study is to assess whether children 12-18 months of age who are exposed to multiple large-scale vitamin A programs, and who are likely to have vitamin A intakes above the tolerable upper intake level (UL), have higher total body vitamin A stores and biomarkers of excessive vitamin A status, compared to children 12-18 months of age who have adequate vitamin A intake.

Study Overview

Detailed Description

This is an observational study with 3 groups, which are identified using a screening tool to obtain information on exposure to vitamin A programs and consumption of vitamin A-rich foods and supplements. Children and their mothers are studied over the course of one month to determine 1) child total body vitamin A stores, using the 13C retinol isotope dilution method, 2) the child's vitamin A intake, using multiple dietary assessment methods, 3) total breast milk intake (among breastfeeding children), using the dose-to-mother deuterium dilution method, and 4) potential biomarkers of excessive vitamin A status, including markers of bone and liver health. Blood collection is structured in a "Super-Child" design, to construct plasma retinol kinetic curves. Other indicators related to vitamin A nutrition among children will be measured, in addition to the vitamin A intake and breast milk vitamin A concentration (for breastfeeding mothers) of the mother.

Study Type

Observational

Enrollment (Actual)

123

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • National Capital Region
      • Mandaluyong, National Capital Region, Philippines
        • Block 37 Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 1 year (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Children 12-18 months of age and their mothers in selected neighborhoods in the National Capital Region of the Philippines

Description

Inclusion Criteria:

  • Children 12-18 months of age, and their mothers (18-49 years of age)
  • Living in selected communities in the National Capital Region of the Philippines
  • The mother and child must plan to stay in the study area for the duration of the study.
  • Child's estimated vitamin A intake and exposure to vitamin A programs must meet eligibility criteria for one of three groups, based on a screening questionnaire administered by an interviewer to the child's mother.

Eligibility criteria for children in Group 1: 1) consumed MNP or a multi-vitamin preparation that contains vitamin A in the previous 7 days, 2) consumed at least one fortified staple food (oil or wheat flour) in the previous 7 days, 3) consumed breast milk or fortified milk in the past 24 hours, 4) received a high-dose VA capsule during the previous month, and 5) received a screening tool 'score' suggesting VA intake above 600 µg retinol/d.

Eligibility criteria for children in Group 2: will include children who: 1) consumed MNP or a multi-vitamin A preparation that contains vitamin A in the previous 7 days, 2) consumed at least one fortified staple food (oil or wheat flour) in the previous 7 days, 3) consumed breast milk or fortified milk in the past 24 hours, 4) received a high-dose VA capsule in the previous 3-6 months, and 5) received a screening tool 'score' suggesting VA intake above 600 µg retinol/d.

Eligibility criteria for children in Group 3: will include children who: 1) received a high dose VA capsule during the previous 3-6 months, and 2) received a screening tool 'score' suggesting VA intake 200-500 µg/d.

Exclusion Criteria:

  • The child did not receive a high-dose VA capsule during the most recent national campaign
  • The mother or child has chronic disease
  • The child has moderate or severe anemia (Hb <10 g/dL)
  • The mother or child has signs or symptoms of vitamin A deficiency (Bitot's spots, conjunctival xerosis, nightblindness)
  • The child has weight for length < -2 z-scores of the median of the WHO growth standards
  • The mother is breastfeeding more than one child

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1: High VA intake, recent VAS
Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
Group 2: High VA intake
Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
Group 3: Low/adequate VA intake
Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total body vitamin A stores among children 12-18 mo of age
Time Frame: 28-day study period
Estimated using the 13C-retinol dilution method
28-day study period
Total dietary vitamin A intake among children 12-18 mo of age
Time Frame: 28-day study period
Estimated using 24-hour dietary recalls, observed weighed food records, food and supplement frequency questionnaire, breast milk vitamin A concentration, and total breast milk intake (measured by the dose-to-mother deuterium dilution technique)
28-day study period
Total breast milk intake (among breastfeeding children 12-18 mo of age)
Time Frame: 15-day study period
Estimating using the dose-to-mother deuterium dilution technique.
15-day study period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma or serum retinol among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Plasma or serum retinol-binding protein among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Ratio of retinol to retinol-binding protein among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Retinol metabolites among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Transthyretin among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Bone health markers among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Liver function markers among children 12-18 mo of age
Time Frame: 28-day study period
28-day study period
Consumption of fortifiable foods among women
Time Frame: 28 day study period
Estimated by combining data from 24-hour recalls, observed weighed food records, food frequency questionnaires, and the Fortification Assessment Coverage Tool
28 day study period
Consumption of fortifiable foods among children
Time Frame: 28 day study period
Estimated by combining data from 24-hour recalls, observed weighed food records, food frequency questionnaires, and the Fortification Assessment Coverage Tool
28 day study period
Total vitamin A intake among women
Time Frame: 28-day study period
Estimated using 24-hour dietary recalls and food frequency questionnaires
28-day study period
Breast milk vitamin A concentration among lactating women
Time Frame: 28-day study period
28-day study period

Other Outcome Measures

Outcome Measure
Time Frame
Total food and nutrient intakes among women
Time Frame: 28-day study period and 30 days prior to study period
28-day study period and 30 days prior to study period
Total food and nutrient intakes among children
Time Frame: 28-day study period and 30 days prior to study period
28-day study period and 30 days prior to study period
Infant weight-for-length z score
Time Frame: At recruitment
At recruitment
Infant length-for-age z score
Time Frame: At recruitment
At recruitment
Systemic inflammation among children
Time Frame: 28-day study period
28-day study period
Iron status among children
Time Frame: 28-day study period
28-day study period
Zinc status among children
Time Frame: 28-day study period
28-day study period
Hepatitis infection among children
Time Frame: 28-day study period
28-day study period
Genetic markers related to vitamin A metabolism among children
Time Frame: 28-day study period
28-day study period
Infant hemoglobin concentration
Time Frame: At enrollment
At enrollment
Infant morbidity symptoms
Time Frame: 28-day study period and previous 7 days
28-day study period and previous 7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2016

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

January 17, 2017

First Submitted That Met QC Criteria

January 20, 2017

First Posted (Estimate)

January 25, 2017

Study Record Updates

Last Update Posted (Actual)

May 4, 2017

Last Update Submitted That Met QC Criteria

May 3, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 903681
  • OPP1115464 (Other Grant/Funding Number: Other)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

To be determined.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin A Status

Clinical Trials on High VA intake, recent VAS

3
Subscribe